Real-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure
Authors' conclusion
In this real-world propensity score-matched cohort, abaloparatide and romosozumab significantly improved BMD and proximal femur structural parameters over the first 12 months of treatment. No significant between-group differences were observed during this period.
Study context
- Population
- Treatment-naïve postmenopausal women with osteoporosis at high fracture risk51 matched per group
- Participants
- 51 vs 51
- Exposure
- Abaloparatide vs romosozumab
- Abaloparatiden = 51
- Romosozumabn = 51
- Outcome
- Percentage changes in lumbar spine, total hip and femoral neck BMD
- Follow-up
- 12 months
Methodological detailsnationwide, multicentre, propensity-score matched, mixed models for repeated measures
- Nationwide
- Multicentre
- Propensity-score matched
- Mixed models for repeated measures
Main finding
As reported in the abstract
Percentage change in BMD (lumbar spine (LS), total hip (TH), femoral neck (FN))
- Significant increases in bone mineral density (BMD) at all skeletal sites in both groups (all P < 0.001)
- No significant between-group differences
Observational data: associations, not effects.
Further findings
Proportion achieving T-score > −2.5
- Increased over time in both groups without significant between-group differences
3D-Shaper trabecular and cortical structural parameters (exploratory) · 12 months
- Improvements in several parameters, no significant between-group differences in any parameter
- Exploratory
Original publication
Real-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure. Osteoporos Int. Published 28 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →